Payment overview · 2025
General Payments
$604.28
38 reported records · 12 companies
Healthcare provider profile · identity verified
David C Powers, MD
Allopathic & Osteopathic Physicians|Family Medicine · SOUTH HILL, VA · NPI 1215933494
Verified facts
What the public records show
CMS Open Payments records show David C Powers, MD received $604.28 in general payments during 2025 across 38 reported records.
Novo Nordisk Inc accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Synjardy by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $176.51 | 29.2% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.95 | 11.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.89 | 10.7% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.50 | 7.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.59 | 7.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.04 | 6.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.45 | 6.7% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.61 | 4.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.01 | 4.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $27.92 | 4.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.41 | 3.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.40 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $604.28 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.50 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.32 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.32 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.50 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.59 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.00 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.45 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.84 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.96 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $29.61 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.01 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $27.92 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 161 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
137 | 32 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
245 | 61 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 934 | 274 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 850 | 254 |
| Amlodipine Besylate | Amlodipine Besylate | 748 | 208 |
| Pantoprazole Sodium | Pantoprazole Sodium | 690 | 213 |
| Losartan Potassium | Losartan Potassium | 640 | 169 |
| Omeprazole | Omeprazole | 448 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 435 | 132 |
| Lisinopril | Lisinopril | 432 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 399 | 120 |
| Gabapentin | Gabapentin | 363 | 123 |
| Metoprolol Tartrate | Metoprolol Tartrate | 357 | 100 |
| Famotidine | Famotidine | 293 | 90 |
| Metformin Hcl | Metformin Hcl | 283 | 88 |
| Allopurinol | Allopurinol | 279 | 80 |
| Furosemide | Furosemide | 270 | 96 |
| Eliquis | Apixaban | 245 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 69 |
| Tramadol Hcl | Tramadol Hcl | 221 | 58 |
| Carvedilol | Carvedilol | 210 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 210 | 62 |
| Montelukast Sodium | Montelukast Sodium | 198 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 179 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 57 |
| Spironolactone | Spironolactone | 171 | 51 |
| Finasteride | Finasteride | 161 | 46 |
| Jardiance | Empagliflozin | 161 | 37 |
| Trazodone Hcl | Trazodone Hcl | 154 | 40 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 151 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 40 |
| Synjardy | Empagliflozin/Metformin Hcl | 137 | 32 |
| Alendronate Sodium | Alendronate Sodium | 131 | 41 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 126 | 126 |
| Sertraline Hcl | Sertraline Hcl | 125 | 33 |
| Memantine Hcl | Memantine Hcl | 120 | 38 |
| Alprazolam | Alprazolam | 116 | 35 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 116 | 31 |
| Prednisone | Prednisone | 112 | 90 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 111 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 30 |
| Metformin Hcl Er | Metformin Hcl | 109 | 37 |
| Benazepril Hcl | Benazepril Hcl | 102 | 28 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 99 | 92 |
| Warfarin Sodium | Warfarin Sodium | 96 | 27 |
| Nitroglycerin | Nitroglycerin | 90 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 17 |
| Farxiga | Dapagliflozin Propanediol | 88 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 22 |
| Ezetimibe | Ezetimibe | 78 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 24 |
| Terbinafine Hcl | Terbinafine Hcl | 67 | 57 |
| Acyclovir | Acyclovir | 65 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 19 |
| Potassium Chloride | Potassium Chloride | 63 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 18 |
| Baclofen | Baclofen | 59 | 25 |
| Simvastatin | Simvastatin | 58 | 20 |
| Cephalexin | Cephalexin | 57 | 55 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 16 |
| Levetiracetam | Levetiracetam | 54 | 16 |
| Glimepiride | Glimepiride | 53 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 35 |
| Colchicine | Colchicine | 51 | 23 |
| Meloxicam | Meloxicam | 51 | 38 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 50 | 50 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 50 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 21 |
| Azithromycin | Azithromycin | 44 | 42 |
| Nystatin | Nystatin | 43 | 27 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | 16 |
| Fenofibrate | Fenofibrate | 41 | 15 |
| Repatha Sureclick | Evolocumab | 41 | 11 |
| Celecoxib | Celecoxib | 40 | 15 |
| Linzess | Linaclotide | 40 | 14 |
| Buspirone Hcl | Buspirone Hcl | 39 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 29 |
| Valsartan | Valsartan | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Folic Acid | Folic Acid | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 28 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 13 |
| Ozempic | Semaglutide | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 28 |
| Bumetanide | Bumetanide | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | 11 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Torsemide | Torsemide | 27 | 11 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 22 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Mesalamine Er | Mesalamine | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $604.28 · 38 records | Novo Nordisk Inc | Cologuard Collection Kit, Dexcom G6 Transmitter, ENTRESTO, FREESTYLE LIBRE 3, JARDIANCE, Korlym, LEQVIO, NURTEC ODT, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, Wegovy, XIFAXAN, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error